# Efficacy and Safety of Rasagiline in Prodromal Parkinson's Disease

> **NCT05611372** · PHASE2,PHASE3 · WITHDRAWN · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University**

## Conditions studied

- REM Sleep Behavior Disorder
- Parkinson Disease
- Synucleinopathies

## Interventions

- **DRUG:** Rasagiline

## Key facts

- **NCT ID:** NCT05611372
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-01-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No suitable recruitment
- **Last updated:** 2025-01-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05611372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05611372, "Efficacy and Safety of Rasagiline in Prodromal Parkinson's Disease". Retrieved via MORVS 2026-10-16 from https://api.morvs.ai/clinical/NCT05611372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*